Spondyloarthritis

Deodhar discusses the results of a study comparing the symptoms and treatment patterns in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis.

The oral therapy filgotinib could be a more effective treatment for patients with active ankylosing spondylitis who fail treatment with NSAIDs, according to the results of a study presented at the Clinical Congress of Rheumatology West in San Diego last month.

Novartis announced the ongoing Phase 3 PREVENT trial examining use of secukinumab in patients with non-radiographic axial spondyloarthritis has met its primary endpoint of ASAS40.

An international physician group writing in the British journal Annals of the Rheumatic Diseases, has updated recommended parameters that constitute lesions in the sacroiliac joints of patients with spondyloarthritis. The definitions of capsulitis, enthesitis, fat lesion and erosion were revised and new definitions were developed for joint space enhancement, joint space fluid, fat metaplasia in an erosion cavity, ankylosis and bone bud.

Previously, smoking was the sole known modifiable predictor of spinal structural damage, but now alcohol consumption has been shown to be associated with the progression of spinal structural damage in axial spondyloarthritis―specifically by increasing the odds of syndesmophyte progression over two years. 

In this slideshow, we highlight 12 recommendations for assessing MRI lesions on the sacroiliac joints of patients with spondyloarthritis. The recommendations were made by the Assessment of Spondyloarthritis International Society (ASAS) MRI working group and published in the British journal Annals of the Rheumatic Diseases earlier this year. 

A 12-week phase 2 study comparing filgotinib to placebo found the oral, selective JAK1-inhibitor could be an effective treatment for ankylosing spondylitis.

A 33-year-old man visits his doctor complaining of a thick scaly plaque on his toes and toenails and low back pain. What's your diagnosis?

Review shows inconsistencies in infliximab concentrations for patients with spondyloarthritis. More research is needed to determin optimal dosages to achieve a clinical response in spondyloarthritis.

Updated treatment recommendations have been issued for ankylosing spondylitis and non-radiographic axial spondyloarthritis. There are 86 recommendations. In this slideshow, we highlight those categorized as "strongly recommended." 

Lilly has announced that it received FDA approval for Taltz (ixekizumab) for the treatment of active ankylosing spondylitis (radiographic axial spondyloarthritis).

The new approval represents the third time the FDA approved the injection treatments for adults.

A new set of guidelines has been released by the American College of Rheumatology, Spondylitis Association of America and the Spondyloarthritis Research and Treatment Network are offering guidance to physicians on treating axial spondyloarthritis.

In this slideshow, we revisit some of our most popular stories on spondyloarthritis published in recent weeks. From making an accurate diagnosis to assessing a confusing case of back pain, learn more in this slideshow.

An Indian-made biosimilar to adalimumab has been shown to be safe and effective for up to 24 weeks in patients with ankylosing spondylitis, say researchers writing in ACR Open Rheumatology this month.

Bone erosion, fat in joint spaces (backfill), and ankylosis visible on MRI could help identify women with axial spondyloarthritis, investigators wrote in a research article published last month in Arthritis & Rheumatology.

The established criteria for radiographic axial spondyloarthritis and axial spondyloarthritis that is classified as ankylosing spondylitis-is essentially the same, report physicians who recommend the interchangeable use of the terms "ankylosing spondylitis" and "radiographic axial spondyloarthritis."

New research shows that a newly identified species of gut bacteria is significantly depleted in patients with ankylosing spondylitis.

High levels of comorbidity burden are associated independently with poor physical function and increased disability in patients with psoriatic arthritis, however, patients ankylosing spondylitis did not report worse function when comorbidities were present.

In an effort to determine what causes immune mediated diseases such as ankylosing spondylitis, inflammatory bowel disease and psoriasis, researchers have focused on learning more about genetic pathogenic pathways responsible for autoimmunity. In this article, we review the data and highlight best practices.

A new study of long-term data demonstrates that infliximab and golimumab are both effective, safe treatments for symptoms of ankylosing spondylitis.

Reactive arthritis is an inflammatory joint arthritis largely characterized by joint inflammation triggered by infection. To date, no diagnostic or classification criteria have been established, but in 2014, the American College of Rheumatology issued general treatment guidelines. In this article, we highlight a new review article on treatments for reactive arthritis.

A 40-year-old man presents to his primary care doctor complaining of pain in his ankles, knees, feet, heels, lower back and buttocks. What's your diagnosis?